State Regulators Struggle to Guide Cannabis Businesses on Schedule III

State cannabis regulators are publicly criticizing the federal government's failure to provide clear guidance on how marijuana's rescheduling to Schedule III will affect licensed businesses, leaving officials unable to answer basic questions from operators about tax implications and compliance requirements.

"None of us really can effectively advise our licensees, which is just incredibly frustrating, especially with a ticking clock," one state marijuana official told Stateline.

The Department of Justice's decision to move cannabis from Schedule I to Schedule III under the Controlled Substances Act represents the most significant federal policy shift on marijuana in decades. Yet state regulators—the front-line officials responsible for overseeing the $30 billion legal cannabis industry—say they've received virtually no guidance from federal agencies on practical implementation details.

The Tax Question

The biggest uncertainty centers on Section 280E of the tax code, which currently prohibits cannabis businesses from deducting ordinary business expenses on federal returns because marijuana is a Schedule I substance. Rescheduling should technically eliminate this restriction, potentially saving the industry billions annually.

But critical questions remain unanswered: When exactly does the tax relief take effect? Can businesses amend previous returns? What documentation will the IRS require? State officials say they're fielding these questions daily from licensees who need to make financial decisions now—not months from now.

The lack of clarity is particularly acute for businesses planning their 2025 budgets and tax strategies. Some companies are proceeding as if 280E still applies, while others are banking on immediate relief. Neither approach comes with certainty.

Banking and Compliance Concerns

Beyond taxes, state regulators are unclear how rescheduling affects banking relationships, interstate commerce restrictions, and existing state-federal agreements on enforcement. Medical marijuana programs in 38 states operate under a patchwork of regulations that were designed around Schedule I status.

"We're getting questions about whether this changes anything for medical research applications, for banking compliance, for interstate transport—and we simply don't have answers," another state official said.

The situation is especially complicated for states with both medical and adult-use programs. Rescheduling technically applies only to medical cannabis, creating potential regulatory splits that states aren't equipped to manage without federal direction.

What Happens Next

The Drug Enforcement Administration finalized the rescheduling rule in January 2025, but implementation details were left to other agencies—primarily the Treasury Department and IRS for tax matters. Those agencies have yet to issue formal guidance.

Industry groups including the National Cannabis Industry Association have been pressing for clarity, arguing that the uncertainty undermines the intended benefits of rescheduling. Some are calling for emergency guidance from the IRS before the April tax filing deadline.

State regulators, meanwhile, are developing contingency plans and encouraging licensees to consult tax professionals. But without federal direction, even the most experienced cannabis attorneys can only offer educated guesses about how to proceed.

The frustration among state officials reflects a broader tension in cannabis policy: states have built sophisticated regulatory systems for legal marijuana, but federal agencies remain largely silent on how those systems should adapt to changing federal classifications.

---

This article is based on original reporting by www.marijuanamoment.net.